Precision surgery and avoiding over-treatment by Hosseini, A, Khoury, A.L, Esserman, L.J

Get full text

1812 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival. Retrospective analyses of th... by Lindström, L.S, Yau, C, Czene, K, Thompson, C.K, Van't Veer, L.J, Nordenskjöld, B, Stål, O, Fornander, T, Benz, C.C, Borowsky, A.D, Esserman, L.J

Get full text

P262 Cost-effectiveness of intraoperative radiation therapy for breast conservation by Alvarado, M.D, Mohan, A.J, Esserman, L.J, Ozanne, E

Get full text

A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients by Barcaru, A., Kuilman, M.M., Wolf, D., Yau, C., Choy, E.B.M., Audeh, W.M., Brown-Swigart, L., Hirst, G.L., Symmans, F.W., Liu, M.C., Nanda, R., Esserman, L.J., van ‘t Veer, L.J., Glas, A.M., Mittempergher, L.

Get full text

Mammographic screening detects low-risk tumor biology breast cancers by Drukker, C. A., Schmidt, M. K., Rutgers, E. J. T., Cardoso, F., Kerlikowske, K., Esserman, L. J., van Leeuwen, F. E., Pijnappel, R. M., Slaets, L., Bogaerts, J., van’t Veer, L. J.

Get full text

P221 by Lang, J.E, Jenkins, T, Hwang, E, Esserman, L.J, Ewing, C.A, Lu, Y, Leong, S.P

Get full text

Expanding the reach of decision and communication aids in a breast care center: A quality improvement study by Belkora, Jeffrey K, Teng, Alexandra, Volz, Shelley, Loth, Meredith K, Esserman, Laura J

Get full text

Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? by Esserman, L. J., Alvarado, M. D., Howe, R. J., Mohan, A. J., Harrison, B., Park, C., O’Donoghue, C., Ozanne, E. M.

Get full text

P221: The ratio between positive and negative lymph nodes strongly predicts adverse outcome in stage I-III breast carcinoma by Lang, J.E., Jenkins, T., Hwang, E., Esserman, L.J., Ewing, C.A., Lu, Y., Leong, S.P.

Get full text

Immune subtyping in the Response Predictive Subtypes (RPS) identifies a subset of triple negative (TN) early-stage breast cancer patients with a very low likelihood of response to... by Wolf, D.M., Yau, C., Haan, J., Wehkamp, D., Witteveen, A., Glas, A., Campbell, M., Nanda, R., Chien, J., Shatsky, R., Isaacs, C., Barcura, A., Mittempergher, L., Kuilman, M., Yee, D., DeMichele, A., Perlmutter, J., Pusztai, L., Esserman, L., van ’t Veer, L.J.

Get full text

532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the... by Glas, A, Peeters, J, Yau, C, Wolf, D.M, Sanil, A, Li, Y, Severson, T, Linn, S, Buxton, M, DeMichele, A, Hylton, N, Symmans, F, Yee, D, Paoloni, M, Esserman, L, Berry, D, Rugo, H, Olopade, O, van 't Veer, L.J

Get full text